Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Decitabine and ATO to Treat AML/MDS Expressing a Classified Type of Mutant p53

NCT03855371 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT03855371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03855371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Decitabine and ATO to Treat AML/MDS Expressing a Classified Type of Mutant p53
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
January 10, 2018
Completion date
July 31, 2024
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml, mds, myeloid malignancy, p53 mutation